In brief aspirin duration following PCI for ACS, no harm occurs.

Published Date: 11 Nov 2023

In the T-PASS trial, less than a month of ticagrelor plus aspirin therapy, followed by ticagrelor alone for a year after PCI for ACS, was found to be noninferior to dual antiplatelet therapy.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Relationship-building key to addressing oncologist shortages in rural care

2.

New protein target discovered for childhood medulloblastomas

3.

Acalabrutinib + Venetoclax Combo Earns FDA Nod for CLL

4.

Papillary thyroid cancer: New markers offer hope for tailored treatment

5.

Jazz Seeks Second-Line Lurbinectedin SCLC Withdrawal


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot